• 1
    Casteels K, Bouillon R, Waer M, Mathieu C. Immunomodulatory effects of 1,25-dihydroxyvitamin D3. Curr Opin Nephrol Hyperten 1995; 4:313 8.
  • 2
    Lemire JM. Immunomodulatory role of 1,25-dihydroxyvitamin D3. J Cell Biochem 1992; 49:26 31.
  • 3
    Hewison M. Vitamin D and the immune system. J Endocrinol 1992; 132:173 5.
  • 4
    Provvedini DM & Manolagas SC. 1,25-Dihydroxyvitamin D3 receptor distribution and effects in subpopulations of normal human T lymphocytes. J Clin Endocrinol Metab 1989; 68:774 9.
  • 5
    D’Ambrosio D, Cippitelli M, Cocciolo MG, Mazzeo D, Di Lucia P, Lang R, Sinigaglia F, Panina-Bordignon P. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-κB downregulation in transcriptional repression of the p40 gene . J Clin Invest 1998; 101:252 62.
  • 6
    Takeuchi A, Reddy GS, Kobayashi T, Okano T, Park J, Sharma S. Nuclear factor of activated T cells (NFAT) as a molecular target for 1α,25-dihydroxyvitamin D3-mediated effects . J Immunol 1998; 160:209 18.
  • 7
    Alroy I, Towers TL, Freedman LP. Transcriptional repression of the interleukin-2 gene by vitamin D3: direct inhibition of NF-ATp/AP-1 complex formation by a nuclear hormone receptor . Mol Cell Biol 1995; 15:5789 99.
  • 8
    Cantorna MT, Woodward WD, Hayes CE, DeLuca HF. 1,25-Dihydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-β 1 and IL-4. J Immunol 1998; 160:5314 9.
  • 9
    Casteels K, Waer M, Laureys J, Valckx D, Depovere J, Bouillon R, Mathieu C. Prevention of autoimmune destruction of syngeneic islet grafts in spontaneously diabetic nonobese diabetic mice by a combination of a vitamin3 analog and cyclosporine. Transplantation 1998; 65:1225 32.
  • 10
    Casteels K, Bouillon R, Waer M, Valckx D, Overbergh L, Laureys J, Mathieu C. Prevention of type I diabetes by late intervention with non-hypercalcemic analogues of vitamin D3 in combination with cyclosporin A. Endocrinology 1998; 139:95 102.
  • 11
    Dusso A, Brown A, Slatopolsky E. Extrarenal production of calcitriol. Semin Nephrol 1994; 14:144 55.
  • 12
    Dusso A, Kamimura S, Gallieni M, Zhong M, Negrea L, Shapiro S, Slatopolsky E. γ-Interferon-induced resistance to 1,25-(OH)2D3 in human monocytes and macrophages: a mechanism for the hypercalcemia of various granulomatoses. J Clin Endocrinol Metab 1997; 82:2222 32.
  • 13
    Adams JS & Ren SY. Autoregulation of 1,25-dihydroxyvitamin D synthesis in macrophage mitochondria by nitric oxide. Endocrinology 1996; 137:4514 7.
  • 14
    Fu GK, Lin D, Zhang MYH, Bikle DD, Shackleton CHL, Miller WL, Portale AA. Cloning of human 25-hydroxyvitamin D-1α-hydroxylase and mutations causing vitamin D-dependent rickets type 1. Mol Endocrinol 1997; 11:1961 70.
  • 15
    Monkawa T, Yoshida T, Wakino S et al. Molecular cloning of cDNA and genomic DNA for human 25-hydroxyvitamin D3 1α-hydroxylase . Biochem Biophys Res Commun 1997; 239:527 33.
  • 16
    Shinki T, Shimada H, Wakino S, Anazawa H, Hayashi M, Saruta T, DeLuca HF, Suda T. Cloning and expression of rat 25-hydroxyvitamin D3-1α-hydroxylase cDNA . Proc Natl Acad Sci USA 1997; 94:12920 5.
  • 17
    Takeyama K, Kitanaka S, Sato T, Kobori M, Yanagisawa J, Kato S. 25-Hydroxyvitamin D3 1α-hydroxylase and vitamin D synthesis . Science 1997; 277:1827 30.
  • 18
    St-Arnaud R, Messerlian S, Moir JM, Omdahl JL, Glorieux FH. The 25-hydroxyvitamin D 1-alpha-hydroxylase gene maps to the pseudovitamin D-deficiency rickets (PDDR) disease locus. J Bone Miner Res 1997; 12:1552 9.
  • 19
    Kato S, Yanagisawa J, Murayama A, Kitanaka S, Takeyama K. The importance of 25-hydroxyvitamin D3 1α-hydroxylase gene in vitamin D-dependent rickets . Curr Opin Nephrol Hypertens 1998; 7:377 83.
  • 20
    Pozzilli P, Signore A, Williams A, Beales P. NOD mouse colonies around the world—recent facts and figures. Immunol Today 1993; 14:193 6.
  • 21
    Menaa C, Vrtovsnik F, Friedlander G, Corvol M, Garabedian M. Insulin-like growth factor I, a unique calcium dependent stimulator of 1,25-dihydroxyvitamin D3 production. J Biol Chem 1995; 270:25461 7.
  • 22
    Overbergh L, Valckx D, Waer M, Mathieu C. Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. Cytokine 1999; 11:305 12.
  • 23
    Gerber DA, Bonham CA, Thomson AW. Immunosuppressive agents: recent developments in molecular action and clinical application. Transplant Proc 1998; 30:1573 9.
  • 24
    Resch K & Szamel M. Molecular mechanisms of the immunosuppressive action of cyclosporin A. Int J Immunopharmacol 1997; 19:579 85.
  • 25
    Branisteanu D, Waer M, Sobis H, Marcelis S, Vandeputte M, Bouillon R. Prevention of murine experimental allergic encephalomyelitis: cooperative effects of cyclosporine and 1α,25-(OH)2D3. J Neuroimmunol 1995; 61:151 160.
  • 26
    Branisteanu D, Mathieu C, Casteels K, Bouillon R. Combination of vitamin D analogues and immunosuppressants. Potential clinical use. Clin Immunother 1996; 6:465 78.
  • 27
    Mathieu C, Casteels K, Waer M, Laureys J, Valckx D, Bouillon R. Prevention of diabetes recurrence after islet transplantation in NOD mice by analogues of 1,25(OH)2D3 in combination with CyA. Transplant Proc 1997; 28:3095.
  • 28
    Adams JS, Modlin RL, Diz MM, Barnes PF. Potentiation of the macrophage 25-hydroxyvitamin D-1-hydroxylation reaction by human tuberculous pleural effusion fluid. J Clin Endocrinol Metab 1989; 69:457 60.
  • 29
    Dick IM, Retallack R, Prince RL. Rapid nongenomic inhibition of renal 25-hydroxyvitamin D3 1-hydroxylase by 1,25-dihydroxyvitamin D3. Am J Physiol 1990; 259:E272 E277.
  • 30
    Reichel H, Koeffler HP, Bishop JE, Norman AW. 25-Hydroxyvitamin D3 metabolism by lipopolysaccharide-stimulated normal human macrophages. J Clin Endocrinol Metab 1987; 64:1 9.
  • 31
    Koeffler HP, Reichel H, Bishop JE, Norman AW. Gamma-interferon stimulates production of 1,25-dihydroxyvitamin D3 by human pulmonary macrophages. Biochem Biophys Res Commun 1985; 127:596 603.
  • 32
    Reichel H, Koeffler HP, Barbers R, Norman AW. Regulation of 1,25-dihydroxyvitamin D3 production by cultured alveolar macrophages from normal human donors and from patients with pulmonary sarcoidosis. J Clin Endocrinol Metab 1987; 65:1201 9.
  • 33
    Henry HL. The 25-hydroxyvitamin D 1α-hydroxylase. In: FeldmanD, GlorieuxFH, PikeJW, eds. Vitamin D. San Diego: Academic Press, 1997: 57 68.
  • 34
    Bikle D, Pillai S, Gee E, Hincenbergs M. Regulation of 1,25-dihydroxyvitamin D production in human keratinocytes by interferon-gamma. Endocrinology 1989; 124:655 60.
  • 35
    Hewison M & O’Riordan JLH. Immunomodulatory and cell differentiation effects of vitamin D. In: FeldmanD, GlorieuxFH, PikeJW, eds. Vitamin D. San Diego: Academic Press, 1997: 447 62.
  • 36
    Mathieu C, Waer M, Laureys J, Rutgeerts O, Bouillon R. Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia 1994; 37:552 8.
  • 37
    Mathieu C, Waer M, Casteels K, Laureys J, Bouillon R. Prevention of type I diabetes in NOD mice by non-hypercalcemic doses of a new structural analogue of 1,25-(OH)2D3, KH1060 . Endocrinology 1995; 136:866 72.
  • 38
    Stein B, Halloran BP, Reinhardt T et al. Cyclosporin-A increases synthesis of 1,25-dihydroxyvitamin D3 in the rat and mouse. Endocrinology 1991; 128:1369 73.